Psyence Biomedical Ltd. (Nasdaq: PBM), also known as Psyence BioMed, is a biopharmaceutical and life sciences biotechnology company focused on nature-derived psilocybin and ibogaine-based psychedelic medicine. Its news flow reflects activity across clinical development, manufacturing, capital markets, and strategic partnerships.
Readers of the PBM news page can expect updates on the company’s Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for Adjustment Disorder in palliative care or in patients with cancer. News releases describe milestones such as patient dosing, expansion of clinical sites in Australia, and ethics approvals for the use of PsyLabs’ psilocybin product in the trial.
The company also issues announcements on its ibogaine operations and supply chain, including the establishment of sustainable iboga bark sourcing in Africa and the production of GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) and Total Alkaloid Extracts through its partner PsyLabs. These updates highlight progress in securing psychedelic active pharmaceutical ingredients for clinical and therapeutic markets.
Other PBM news items cover strategic investments and financial decisions, such as follow-on investments in PsyLabs, share consolidation (reverse stock split) actions, and capital management frameworks that include potential share repurchase programs, as described by the company. Communications may also address leadership changes, board appointments, and corporate governance developments disclosed in conjunction with SEC filings.
In addition, Psyence BioMed publishes news on its psilocybin longevity research initiative, which examines biological markers associated with aging, and on its broader positioning in the emerging psychedelics and longevity sectors. Investors and observers who follow PBM news can use this page to track the company’s clinical progress, manufacturing capabilities, and regulatory and capital markets updates over time.
Psyence BioMed (Nasdaq: PBM) completed a US$2,599,896 additional investment in PsyLabs after both milestones supporting its backstop commitment were met. Its subsidiary subscribed for 1,014 PsyLabs ordinary shares at US$2,564 each, reflecting a US$54 million pre-money equity valuation. Psyence BioMed’s ownership rose from approximately 41.13% to approximately 43.37%.
PsyLabs completed regulatory-readiness documentation for ibogaine hydrochloride, and wholly owned Texas Ibogaine Research Corporation (TIRC) signed a manufacturing agreement with Benuvia. The company intends the agreement to support U.S. pharmaceutical-grade ibogaine production under current Good Manufacturing Practice standards, subject to applicable regulatory requirements. PsyLabs is expected to become TIRC’s exclusive U.S. ibogaine supplier, subject to a definitive agreement the parties agreed to conclude by November 30, 2026.
Psyence BioMed (PBM) has entered a manufacturing partnership through its Texas subsidiary TIRC with Benuvia Operations for planned U.S. ibogaine production. The manufacturing services agreement covers pharmaceutical-grade ibogaine active pharmaceutical ingredient, the drug substance, under current Good Manufacturing Practice standards. Benuvia operates an approximately 83,000-square-foot, DEA-registered facility in Round Rock, Texas.
The partnership is intended to link manufacturing with TIRC’s planned exclusive U.S. license, supply and wholesale distribution arrangement with PsyLabs. Their binding term sheet is to be replaced by a definitive agreement by November 30, 2026. Benuvia is advancing applications for the required DEA import permit and procurement quota. Psyence BioMed expects production timing and scale to depend primarily on DEA quotas, import requirements and other regulatory authorizations.
Psyence BioMed (PBM) announced that its Texas subsidiary TIRC signed a binding term sheet with PsyLabs for exclusive U.S. ibogaine rights. The proposed arrangement covers development know-how, exclusive supply and wholesale distribution of PsyLabs’ pharmaceutical-grade ibogaine. The parties must sign a definitive agreement by November 30, 2026, or the term sheet lapses.
TIRC would pay up to approximately US$1.3 million in development and regulatory milestones for the first drug candidate, plus an annual exclusivity fee after the first FDA approval, royalties on net sales and resale margin sharing. Its planned U.S. development program depends on a final agreement and manufacturing, nonclinical and regulatory work before any clinical investigation can be proposed.
Psyence BioMed (PBM) plans a U.S. ibogaine program and has structured a cash investment and share exchange with PsyLabs to support it.
The company has formed Texas Ibogaine Research Corporation (TIRC) in Texas to coordinate planned U.S. regulatory, clinical and development work for a potential ibogaine clinical trial in Opioid Use Disorder, which remains subject to protocol design, regulatory and institutional approvals, funding and other requirements. Psyence BioMed agreed to invest up to US$5 million in PsyLabs, including an irrevocably committed US$2.4 million in the current PsyLabs financing round and up to US$2.6 million in two milestone-based backstop tranches that expire if not called by December 31, 2026.
Psyence BioMed and PsyLabs also agreed to a reciprocal share-for-share exchange, with each side valued at about US$9 million, under which Psyence BioMed will issue 1,497,500 common shares at a deemed price of US$6.00 per share and PsyLabs will issue 3,473 ordinary shares based on a US$60 million PsyLabs valuation. Following completion of the share exchange and the committed cash investment, PsyLabs’ ownership of Psyence BioMed will increase from 30.22% to 49.89%, while Psyence BioMed’s stake in PsyLabs will rise from 29.17% to 41.13%.
Psyence BioMed (PBM) has formed Texas Ibogaine Research Corporation (TIRC), a Texas-based company created to coordinate its U.S. ibogaine development activities, including pharmaceutical-grade supply, regulatory engagement and potential clinical development.
TIRC is intended to act as Psyence BioMed’s dedicated U.S. vehicle for regulated ibogaine development and, subject to definitive licensing arrangements, is positioned to hold U.S. rights to pharmaceutical-grade ibogaine developed by PsyLabs, in which Psyence BioMed holds an ownership interest. The new entity will coordinate rights, manufacturing arrangements, regulatory documentation and any future investigational new drug application within a single U.S. company financed by Psyence BioMed. Psyence BioMed CEO Jody Aufrichtig will also serve as TIRC CEO, with Dr. John Thorne appointed project lead and oversight from the company’s existing finance and legal functions.
Psyence BioMed (Nasdaq: PBM), a biopharmaceutical company focused on nature-derived psychedelic compounds, welcomed President Donald J. Trump’s August 18, 2026 announcement supporting accelerated ibogaine development in the U.S. The President cited renewed work with the University of Miami’s 1994 ibogaine IND and highlighted HHS funding, HHS‑VA collaboration, FDA guidance and efforts to expand Right to Try access for veterans.
According to Psyence BioMed, this growing federal commitment aligns with its vertically integrated ibogaine platform, centered on its ownership interest in PsyLabs, which manufactures GMP-compliant ibogaine hydrochloride. The company’s CEO and CFO are in Texas meeting stakeholders to discuss regulatory developments and opportunities for responsible ibogaine clinical development.
Psyence BioMed (Nasdaq: PBM) announced a U.S. strategic engagement initiative focused on GMP ibogaine research and manufacturing. Executives will meet U.S. researchers, institutions, industry leaders, and government stakeholders to discuss regulatory, scientific, and infrastructure needs for pharmaceutical-grade ibogaine suitable for regulated clinical research.
Through its PsyLabs investment, the company operates a GMP-compliant facility in Southern Africa, supporting ethical sourcing, cultivation, extraction, purification, and scalable manufacturing of natural psychedelic compounds, including ibogaine. Psyence BioMed reports growing interest from U.S.-based researchers seeking compliant ibogaine supply for future regulated studies.
Psyence BioMed (Nasdaq: PBM) announced dosing of the first patient in its Phase IIb trial of NPX-5 (25mg nature-derived psilocybin) for Adjustment Disorder in patients with cancer in palliative care. The randomized, double-blind, three-arm study is active across five Australian sites and will collect safety, tolerability, clinical response, and durability data to inform future development and potential regulatory pathways.
The program uses GMP-compliant drug supply and a therapy-supported treatment model as part of the company’s vertically integrated platform.
Psyence BioMed (NASDAQ: PBM) says it has built a GMP-compliant, vertically integrated ibogaine supply chain via investment and collaboration with PsyLabs, operating at the natural source in Africa. The company holds standardized, stabilized GMP ibogaine doses in inventory to support clinical research and potential commercialization.
Platform covers sourcing, extraction, purification, pharmaceutical manufacturing, traceability, and ethical in-region processing.
Psyence BioMed (Nasdaq: PBM) on April 17, 2026 acknowledged U.S. executive action preparations to evaluate ibogaine’s safety and therapeutic potential, while emphasizing its global leadership in GMP ibogaine manufacturing and an ethically sourced supply chain via PsyLabs.
Ibogaine remains a Schedule I substance in the U.S.; the company says controlled clinical research and standardized supply are essential to improve patient safety and enable regulated development.